Skip to main content
Top
Published in: Annals of Hematology 6/2017

01-06-2017 | Original Article

Impact of cachexia on outcomes in aggressive lymphomas

Authors: Reem Karmali, Taha Alrifai, Ibtihaj A. M. Fughhi, Ronald Ng, Vineela Chukkapalli, Palmi Shah, Sanjib Basu, Sunita Nathan, Kelly Szymanski-Grant, Leo I. Gordon, Parameswaran Venugopal, Frank J. Penedo, Jeffrey A. Borgia

Published in: Annals of Hematology | Issue 6/2017

Login to get access

Abstract

Cancer cachexia is defined as a state of involuntary weight loss, attributed to altered body composition with muscle mass loss and/or loss of adiposity. Identifying the association between cancer cachexia and outcomes may pave the way for novel agents that target the cancer cachexia process. Clinical parameters for measurement of cancer cachexia are needed. We conducted a single-institution retrospective analysis that included 86 NHL patients with the aim of identifying an association between cancer cachexia and outcomes in aggressive lymphomas using the cachexia index (CXI) suggested by Jafri et al. (Clin Med Insights Oncol 9:87–93, 15). Impact of cachexia factors on progression-free survival (PFS) and overall survival (OS) were assessed using log-rank test and Cox proportional hazards regression. Patients were dichotomized around the median CXI into “non-cachectic” (CXI ≥49.8, n = 41) and “cachectic” (CXI <49.8, n = 40) groups. Cachectic patients had significantly worse PFS (HR 2.18, p = 0.044) and OS (HR = 4.05, p = 0.004) than non-cachectic patients. Cachexia as defined by the CXI is prognostic in aggressive lymphomas and implies that novel therapeutic strategies directed at reversing cachexia may improve survival in this population.
Literature
1.
go back to reference Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 83(5):1165–1173PubMed Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 83(5):1165–1173PubMed
2.
3.
go back to reference Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13(10):2600–2605CrossRefPubMed Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13(10):2600–2605CrossRefPubMed
4.
go back to reference Kuroda K, Nakashima J, Kanao K et al (2007) Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69(1):113–117CrossRefPubMed Kuroda K, Nakashima J, Kanao K et al (2007) Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69(1):113–117CrossRefPubMed
5.
go back to reference Demetrius LA, Coy JF, Tuszynski JA. (2010) Cancer proliferation and therapy: the Warburg effect and quantum metabolism. Theor Biol Med Model. 7:2. doi:10.1186/1742-4682-7-2 Demetrius LA, Coy JF, Tuszynski JA. (2010) Cancer proliferation and therapy: the Warburg effect and quantum metabolism. Theor Biol Med Model. 7:2. doi:10.​1186/​1742-4682-7-2
6.
go back to reference Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF, Saris WH (1990) Energy balance in relation to cancer cachexia. Clin Nutr 9(6):319–324CrossRefPubMed Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF, Saris WH (1990) Energy balance in relation to cancer cachexia. Clin Nutr 9(6):319–324CrossRefPubMed
8.
go back to reference Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219(4):325–331CrossRefPubMedPubMedCentral Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219(4):325–331CrossRefPubMedPubMedCentral
9.
go back to reference Ohnuma T. 2003 Manifestations of Cachexia. Holland-Frei Cancer Medicine. Hamilton Ohnuma T. 2003 Manifestations of Cachexia. Holland-Frei Cancer Medicine. Hamilton
10.
go back to reference Project TIN-HsLPF (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 329:987–994CrossRef Project TIN-HsLPF (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 329:987–994CrossRef
11.
go back to reference Perry AM, Alvarado-Bernal Y, Laurini JA et al (2014) MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 165(3):382–391CrossRefPubMed Perry AM, Alvarado-Bernal Y, Laurini JA et al (2014) MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 165(3):382–391CrossRefPubMed
12.
go back to reference Lenz G, Wright G, Dave SS et al (2008) Lymphoma/leukemia molecular profiling project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323CrossRefPubMed Lenz G, Wright G, Dave SS et al (2008) Lymphoma/leukemia molecular profiling project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323CrossRefPubMed
13.
go back to reference Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F et al (2010) Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leukemia & Lymphoma 51(7):1305–1314CrossRef Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F et al (2010) Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leukemia & Lymphoma 51(7):1305–1314CrossRef
14.
go back to reference Carbone A, Gloghini A, Kwong Y-L, Younes A (2014) Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 93(8):1263–1277CrossRefPubMedPubMedCentral Carbone A, Gloghini A, Kwong Y-L, Younes A (2014) Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 93(8):1263–1277CrossRefPubMedPubMedCentral
15.
16.
go back to reference Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMed Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMed
17.
go back to reference Prado CM, Sawyer MB, Ghosh S et al (2013) Central tenet of cancer cachexia therapy: do patient with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98:1012–1019CrossRefPubMed Prado CM, Sawyer MB, Ghosh S et al (2013) Central tenet of cancer cachexia therapy: do patient with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98:1012–1019CrossRefPubMed
18.
go back to reference Camus V, Lanic H, Kraut J et al (2014) Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol 93(1):9–18CrossRefPubMed Camus V, Lanic H, Kraut J et al (2014) Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol 93(1):9–18CrossRefPubMed
19.
go back to reference Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, Stamatoullas A, Leprêtre S, Tilly H, Jardin F (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55(4):817–823CrossRefPubMed Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, Stamatoullas A, Leprêtre S, Tilly H, Jardin F (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55(4):817–823CrossRefPubMed
20.
go back to reference Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69CrossRefPubMedPubMedCentral Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69CrossRefPubMedPubMedCentral
21.
go back to reference Lin GN, Peng JW, Liu PP, Liu DY, Xiao JJ, Chen XQ (2014) Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol. doi:10.1111/ajco.12273. [Epub ahead of print] Lin GN, Peng JW, Liu PP, Liu DY, Xiao JJ, Chen XQ (2014) Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol. doi:10.​1111/​ajco.​12273. [Epub ahead of print]
23.
go back to reference Charbonneau B, Maurer MJ, Ansell SM et al (2012) Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 60(3):882–889CrossRefPubMedPubMedCentral Charbonneau B, Maurer MJ, Ansell SM et al (2012) Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 60(3):882–889CrossRefPubMedPubMedCentral
24.
go back to reference Bonetto A, Aydogdu T, Jin X et al (2012) JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 303(3):E410–E421CrossRefPubMedPubMedCentral Bonetto A, Aydogdu T, Jin X et al (2012) JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 303(3):E410–E421CrossRefPubMedPubMedCentral
25.
go back to reference Bonetto A, Penna F, Aversa Z et al (2013) Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve 48(3):387–392CrossRefPubMed Bonetto A, Penna F, Aversa Z et al (2013) Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve 48(3):387–392CrossRefPubMed
26.
go back to reference Karmali R, Dalovisio A, Borgia JA et al (2015) All in the family: clueing into the link between metabolic syndrome and hematologic malignancies. Blood Rev 29(2):71–80CrossRefPubMed Karmali R, Dalovisio A, Borgia JA et al (2015) All in the family: clueing into the link between metabolic syndrome and hematologic malignancies. Blood Rev 29(2):71–80CrossRefPubMed
27.
go back to reference Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd (2013) Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol (1):161–70 Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd (2013) Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol (1):161–70
28.
go back to reference Vishwamitra D, Shi P, Wilson D et al (2011) Expression and effects of inhibition of type 1 insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Heamatolgica 96(6):871–880CrossRef Vishwamitra D, Shi P, Wilson D et al (2011) Expression and effects of inhibition of type 1 insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Heamatolgica 96(6):871–880CrossRef
Metadata
Title
Impact of cachexia on outcomes in aggressive lymphomas
Authors
Reem Karmali
Taha Alrifai
Ibtihaj A. M. Fughhi
Ronald Ng
Vineela Chukkapalli
Palmi Shah
Sanjib Basu
Sunita Nathan
Kelly Szymanski-Grant
Leo I. Gordon
Parameswaran Venugopal
Frank J. Penedo
Jeffrey A. Borgia
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 6/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-2958-1

Other articles of this Issue 6/2017

Annals of Hematology 6/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.